REFRACTORY ACUTE MYELOGENOUS LEUKEMIA (AML)

Clinical trials for REFRACTORY ACUTE MYELOGENOUS LEUKEMIA (AML) explained in plain language.

Never miss a new study

Get alerted when new REFRACTORY ACUTE MYELOGENOUS LEUKEMIA (AML) trials appear

Sign up with your email to follow new studies for REFRACTORY ACUTE MYELOGENOUS LEUKEMIA (AML), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet finished but already full! 1

New drug tested on kids with Tough-to-Treat leukemia

Disease control Ongoing

This early-stage study is testing a new drug called KPT-330 in children and young adults whose leukemia has returned or stopped responding to standard treatments. The main goal is to find the highest safe dose and understand the side effects. Researchers will give different dose …

Matched conditions: REFRACTORY ACUTE MYELOGENOUS LEUKEMIA (AML)

Phase: PHASE1 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control

Last updated Apr 02, 2026 12:12 UTC

REFRACTORY ACUTE MYELOGENOUS LEUKEMIA (AML)

Get alerted when new REFRACTORY ACUTE MYELOGENOUS LEUKEMIA (AML) trials appear

New drug tested on kids with Tough-to-Treat leukemia